MedPath

6-O-benzylguanine

Generic Name
6-O-benzylguanine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C12H11N5O
CAS Number
19916-73-5
Unique Ingredient Identifier
01KC87F8FE
Background

6-O-benzylguanine has been used in trials studying the treatment of HIV Infection, Adult Gliosarcoma, Adult Glioblastoma, Stage I Adult Hodgkin Lymphoma, and Stage II Adult Hodgkin Lymphoma, among others.

Associated Conditions
-
Associated Therapies
-

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

Phase 1
Completed
Conditions
Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Interventions
Drug: Carmustine
Other: Laboratory Biomarker Analysis
Drug: O6-Benzylguanine
First Posted Date
2009-08-18
Last Posted Date
2018-05-22
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
17
Registration Number
NCT00961220
Locations
🇺🇸

Henry Ford Hospital, Detroit, Michigan, United States

🇺🇸

Case Comprehensive Cancer Center, Cleveland, Ohio, United States

🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 1 locations

O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy

Phase 2
Terminated
Conditions
Brain and Central Nervous System Tumors
Interventions
First Posted Date
2007-02-19
Last Posted Date
2017-03-28
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
12
Registration Number
NCT00436436
Locations
🇺🇸

Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

🇺🇸

NCI - Neuro-Oncology Branch, Bethesda, Maryland, United States

O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors

Phase 2
Completed
Conditions
Brain and Central Nervous System Tumors
Interventions
First Posted Date
2006-01-11
Last Posted Date
2022-02-11
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
41
Registration Number
NCT00275002
Locations
🇺🇸

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

🇺🇸

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 8 locations

Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors

Phase 1
Terminated
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
First Posted Date
2004-07-12
Last Posted Date
2013-01-24
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
32
Registration Number
NCT00086970
Locations
🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma

Phase 1
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2004-05-03
Last Posted Date
2009-02-09
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT00004892
Locations
🇺🇸

Henry Ford Hospital, Detroit, Michigan, United States

🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

🇺🇸

University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

and more 6 locations

O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors

Phase 1
Completed
Conditions
Brain and Central Nervous System Tumors
Interventions
First Posted Date
2004-04-27
Last Posted Date
2013-02-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
36
Registration Number
NCT00003765
Locations
🇺🇸

Emory University Hospital - Atlanta, Atlanta, Georgia, United States

🇺🇸

Simmons Cancer Center - Dallas, Dallas, Texas, United States

🇺🇸

Indiana University Cancer Center, Indianapolis, Indiana, United States

and more 53 locations

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

Phase 2
Completed
Conditions
Melanoma (Skin)
Interventions
First Posted Date
2003-01-27
Last Posted Date
2013-02-11
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
40
Registration Number
NCT00005961
Locations
🇺🇸

University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States

🇺🇸

Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States

🇺🇸

Evanston Northwestern Health Care, Evanston, Illinois, United States

and more 10 locations

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

Phase 1
Completed
Conditions
Brain and Central Nervous System Tumors
Childhood Germ Cell Tumor
Neuroblastoma
Unspecified Childhood Solid Tumor, Protocol Specific
Extragonadal Germ Cell Tumor
Sarcoma
Kidney Cancer
Liver Cancer
Ovarian Cancer
First Posted Date
2003-01-27
Last Posted Date
2015-04-29
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT00020150
Locations
🇺🇸

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

Phase 1
Terminated
Conditions
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
Interventions
Drug: O6-benzylguanine
Drug: carmustine
Other: laboratory biomarker analysis
First Posted Date
2003-01-27
Last Posted Date
2013-01-11
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
20
Registration Number
NCT00003613
Locations
🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors

Phase 1
Completed
Conditions
Childhood Ependymoblastoma
Childhood Central Nervous System Germ Cell Tumor
Childhood Choroid Plexus Tumor
Childhood Craniopharyngioma
Childhood Grade I Meningioma
Childhood Grade II Meningioma
Childhood Grade III Meningioma
Childhood High-grade Cerebellar Astrocytoma
Childhood High-grade Cerebral Astrocytoma
Childhood Infratentorial Ependymoma
Interventions
Drug: O6-benzylguanine
Drug: temozolomide
Biological: filgrastim
Other: pharmacological study
Other: laboratory biomarker analysis
First Posted Date
2003-01-27
Last Posted Date
2013-09-30
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
72
Registration Number
NCT00052780
Locations
🇺🇸

Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath